Key Points
- Director Richard Douglas bought 70,000 shares at $1.40 on March 19, boosting his stake 56% to 195,000 shares (about $273,000) as disclosed in an SEC filing.
- Shares trade near $1.81 (down 1.1%) and well below the 50- and 200-day averages, with heavy put activity, lawsuits and increased volatility following an FDA Complete Response Letter for reproxalap.
- Analysts are mixed: HC Wainwright cut its price target to $2 and trimmed EPS forecasts, Wall Street Zen moved to a sell, BTIG remains a buy, and the consensus rating is a Hold with a $5.50 target.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) Director Richard Douglas acquired 70,000 shares of the company's stock in a transaction dated Thursday, March 19th. The stock was acquired at an average cost of $1.40 per share, with a total value of $98,000.00. Following the purchase, the director owned 195,000 shares of the company's stock, valued at approximately $273,000. This trade represents a 56.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.
Aldeyra Therapeutics Trading Down 1.1%
Shares of ALDX opened at $1.81 on Friday. The business's 50 day moving average is $4.78 and its 200 day moving average is $5.00. The company has a market capitalization of $108.93 million, a PE ratio of -3.18 and a beta of 0.97. Aldeyra Therapeutics, Inc. has a 12-month low of $1.07 and a 12-month high of $6.81.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last posted its quarterly earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. Equities research analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.
Trending Headlines about Aldeyra Therapeutics
Here are the key news stories impacting Aldeyra Therapeutics this week:
- Positive Sentiment: Insider buying: Director/insider Michael Alfieri increased his stake, purchasing 5,000 shares at ~$1.42 on March 18 — a modest signal of insider conviction that can be viewed as supportive amid the sell-off. SEC Filing: Insider Purchase
- Neutral Sentiment: Broker note status: HC Wainwright reaffirmed a Neutral rating and a $2.00 target while publishing updated model revisions. The Neutral stance limits upside endorsement from that shop but keeps coverage steady. HC Wainwright Reaffirms Neutral Rating
- Negative Sentiment: Analyst cuts: HC Wainwright sharply reduced EPS forecasts across 2026–2030 (Q4 2026 from $0.27 to ($0.02); FY2026 to ($0.44); FY2027 to ($0.27); FY2028–2030 also lowered). The revisions signal weaker expected profitability and push down research-driven valuation support. HC Wainwright Research Note
- Negative Sentiment: Lawsuits / investigations: Multiple law firms (Pomerantz; Levi & Korsinsky and others) have launched securities-fraud probes and class-action recruitment, alleging management misstatements around reproxalap’s efficacy and approval prospects. Litigation risk and potential disclosures raise investor uncertainty. Pomerantz Investigation Notice Levi & Korsinsky Alert
- Negative Sentiment: Market reaction / put buying: Heavy put-option activity and a multi-day slump (reports cite ~67% decline since Tuesday) indicate aggressive bearish positioning and rapid de-risking by traders following the FDA Complete Response Letter for reproxalap. That pressure has driven large volume and volatility. Put Options Flow Benzinga: What's Going On
- Neutral Sentiment: Short-interest reports in recent feeds show inconsistent/zero values (likely data anomalies); treat reported short metrics cautiously until exchanges refresh official figures. No reliable signal from those entries.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the stock. HC Wainwright reiterated a "neutral" rating and issued a $2.00 price target (down from $10.00) on shares of Aldeyra Therapeutics in a report on Wednesday. Wall Street Zen downgraded shares of Aldeyra Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Finally, BTIG Research reaffirmed a "buy" rating on shares of Aldeyra Therapeutics in a report on Tuesday. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Aldeyra Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $5.50.
Get Our Latest Research Report on ALDX
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. 683 Capital Management LLC raised its stake in Aldeyra Therapeutics by 126.9% during the second quarter. 683 Capital Management LLC now owns 1,080,000 shares of the biotechnology company's stock valued at $4,136,000 after purchasing an additional 604,000 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Aldeyra Therapeutics in the 3rd quarter worth $721,000. CWM LLC grew its stake in shares of Aldeyra Therapeutics by 39.8% in the 3rd quarter. CWM LLC now owns 58,379 shares of the biotechnology company's stock worth $305,000 after buying an additional 16,621 shares in the last quarter. Brighton Jones LLC increased its holdings in shares of Aldeyra Therapeutics by 11.4% in the 3rd quarter. Brighton Jones LLC now owns 19,945 shares of the biotechnology company's stock worth $104,000 after buying an additional 2,046 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at about $52,000. 59.71% of the stock is owned by hedge funds and other institutional investors.
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company's research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.
The company's lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
